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Background: People who inject drugs (PWID) are at high risk of contracting and transmitting and hepatitis C virus
(HCV). While accurate screening tests and effective treatment are increasingly available, prior research indicates that
many PWID are unaware of their HCV status.
Methods: We examined characteristics associated with HCV screening among 553 PWID utilizing a free, multi-site
syringe exchange program (SEP) in 7 cities throughout Wisconsin. All participants completed an 88-item, computerized
survey assessing past experiences with HCV testing, HCV transmission risk behaviors, and drug use patterns. A subset of
362 clients responded to a series of open-ended questions eliciting their perceptions of barriers and facilitators to
screening for HCV. Transcripts of these responses were analyzed qualitatively using thematic analysis.
Results: Most respondents (88%) reported receiving a HCV test in the past, and most of these (74%) were tested
during the preceding 12 months. Despite the availability of free HCV screening at the SEP, fewer than 20% of
respondents had ever received a test at a syringe exchange site. Clients were more likely to receive HCV screening in
the past year if they had a primary care provider, higher educational attainment, lived in a large metropolitan area, and
a prior history of opioid overdose. Themes identified through qualitative analysis suggested important roles of access
to medical care and prevention services, and nonjudgmental providers.
Conclusions: Our results suggest that drug-injecting individuals who reside in non-urban settings, who have poor access
to primary care, or who have less education may encounter significant barriers to routine HCV screening. Expanded access
to primary health care and prevention services, especially in non-urban areas, could address an unmet need for individuals
at high risk for HCV.
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Infection with hepatitis C virus (HCV) is the most com-
mon cause of end-stage liver disease and the most fre-
quent reason for liver transplantation in the United States
[1]. Between 3 and 4 million Americans are chronically in-
fected, many of whom will develop cirrhosis and liver can-
cer in the coming decades. Because of non-sterile
injecting practices, HCV is highly concentrated among* Correspondence: jbarocas@medicine.wisc.edu
1Department of Medicine, University of Wisconsin School of Medicine and
Public Health, 1685 Highland Ave, UWMFCB 5th floor, Madison, WI 53705,
USA
Full list of author information is available at the end of the article
© 2014 Barocas et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.people who inject drugs (PWID) [2,3]. The HCV preva-
lence in a study of young PWID in four large US cities
was 35%, ranging from 14% in Chicago to 51% in New
York City [4]. Among some cohorts of older PWID, HCV
prevalence reportedly exceeds 90% [5,6]. Despite this high
prevalence, prior research has shown that many PWID,
particularly those younger than 30, are unaware of their
status [7,8].
Health care costs associated with HCV infection are
substantial and forecasted to rise dramatically over the
next decade as “baby boomers,” the birth cohort with the
highest HCV prevalence, age into the 7th and 8th decade
of life [9]. HCV-infected persons have been estimated tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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hospitalizationat three times the rate of HCV-uninfected
individuals, after controlling for age and sex [10].
In May 2011, the U.S. Food and Drug Administration
(FDA) approved the first two HCV protease inhibitors
for the treatment of chronic HCV infection in combin-
ation with standard interferon-based therapy [11]. Avail-
ability of direct-acting, antiviral drugs represent a new
era in therapeutics when most patients with chronic
HCV can be cured using agents for a shorter duration
and that have a more favorable side effect profile than
prior regimens. The prospect that these advances will
translate to population-level declines in HCV disease is
currently limited by the fact that 50% to 75% of all
HCV-infected individuals in the U.S. are unaware of
their serostatus [1]. National initiatives to increase case
finding have been proposed, including recommendations
for routine screening in health care settings [12]. Many
PWID and other high-risk individuals lack insurance,
however, and may be systematically underserved by clinic-
based approaches [2]. Therefore, community-based ap-
proaches are also needed to ensure PWID receive HCV
screening.
As PWID are a difficult-to-reach population, little is
known about the characteristics of those who are and
are not screened for HCV. Understanding facilitators
and barriers to HCV screening that are encountered
by PWID may help guide the construction of interven-
tions aimed at reducing the burden of unrecognized HCV
infection. The objectives of this study were to (1) identify
individual characteristics associated with HCV screening
among PWID who utilized a free needle-exchange pro-
gram and (2) identify perceived barriers and facilitators of
HCV screening among a convenience sample of PWID in
the Midwestern United States.
Methods
Study participants
We surveyed PWID utilizing a free, multi-site syringe
exchange program (SEP) operating in Southern Wisconsin
between June and August 2012. The Lifepoint Needle
Exchange operates through office-based locations in the
cities of Madison and Milwaukee, and via mobile van
units that serve the Milwaukee suburbs, rural communi-
ties surrounding Madison, and the cities of Kenosha,
Waukesha, Janesville and Beloit. Consecutive individ-
uals who speak and read English, were 18 years or
older, and reported a history of injecting drugs were
invited to participate. Participants provided verbal
informed consent and were paid $10 in cash as com-
pensation for completing the survey. The study protocol
was approved by the Institutional Review Board at
the University of Wisconsin School of Medicine and
Public Health.Survey administration
We developed an 88-item questionnaire designed to elicit
previous experiences with HCV testing. Survey items
assessed demographic characteristics, drug use behaviors
(e.g., frequency of injection, sharing needles or equipment,
and overdose history), and access to medical care (e.g.,
emergency room utilization, having a primary care pro-
vider). Participants were queried about the frequency of
previous HCV testing, the results of past HCV tests, and
the locations they had received testing. Multiple-choice
and short-answer question items were self-administered
by the client, who read the survey and recorded responses
using a tablet computer. This allowed respondents to pro-
vide information dealing with sensitive subjects such as
illicit drug use in a private manner, decreasing the likeli-
hood of socially desirable responding.
A second phase of the assessment was a brief interview
consisting of several open-ended questions that evaluated
participants’ previous experiences with HCV testing.
Development of the brief interview items was guided by
the Health Belief Model [13-15] and focused on bar-
riers, facilitators and previous experiences with seeking
and receiving testing for HCV. The two question items
relevant to the current analysis were (1) “What makes
it harder for you to get tested for hepatitis C?” and (2)
“What makes it easier for you to get tested for hepatitis
C?” Responses were hand-transcribed by the inter-
viewer in real time on the tablet computer. Interviewers
were instructed to record participants’ responses verba-
tim. The text of each response was linked to an an-
onymous identification number assigned to the
participant’s survey responses and saved for subsequent
thematic analysis, as described below.
Quantitative data analysis
Descriptive statistics were used to characterize the study
sample with respect to the main variable of interest,
which was self-report of receiving HCV screening during
the previous 12 months. After excluding respondents
who reported already knowing they were HCV-positive,
we categorized the study sample in two groups, those
who reported having received an HCV test in the past
year and those who had not. The latter group includes
those who have never tested and whose last HCV test
was more than one year prior to the study, because the
health behavior of the latter group is inconsistent with
HCV testing recommendations.
We compared demographic and behavioral characteristics
of the two subsets of respondents using t-tests for continu-
ous variables and chi-squared tests for categorical variables.
We used simple logistic regression to generate odds ratios
and 95% confidence intervals representing bivariate associa-
tions between past-year HCV testing and individual charac-
teristics we hypothesized would be important determinants
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statistical significance. To identify factors independently
associated with past-year HCV testing, we used multiple
logistic regression models to estimate adjusted odds ratios.
Variables with significant bivariate associations and those
considered a priori to be likely predictors of HCV testing
were included in an initial multivariate model. A final
model was determined by sequentially eliminating covari-
ates with non-significant P-values. Statistical analyses were
conducted using STATAVersion 11 (Cary, NC).
Qualitative data analysis
Two investigators (JB and MB) conducted the qualitative
analysis using an inductive thematic approach [16,17]. First,
investigators independently read all interview transcripts for
main themes and subcategories. They then met to develop
consensus over a coding scheme used for further analysis.
Both investigators independently coded all transcripts
line-by-line using the coding scheme and discrepancies
were resolved by discussion to reach consensus. Inter-
rater reliability was 81%. To explore whether barriers
and facilitators are perceived differently by respondents
tested for HCV in the past year compared to those who
were not, we compared the frequency of specific codes




Over the 8-week study period, 862 consecutive syringe
exchange clients were invited to participate in the study
and 553 eligible PWID (64%) agreed to complete the
survey. For the present analysis, we excluded 33 respon-
dents who reported knowing they were HCV-infected
and received their diagnosis more than 1 year ago be-
cause they would have no reason to be tested in the past
12 months, yielding a final study sample of 520. Most re-
spondents resided in the City of Milwaukee (34.9%) or the
Milwaukee suburbs (19.2%). A smaller proportion was re-
cruited from the Madison-based office (19.5%), which serves
the City of Madison and surrounding, predominantly rural
communities.
Characteristics of the study participants are shown in
Table 1, stratified by whether they reported testing in the
past year. The median age was 28; most participants were
male (69%) and white (83%). The neighborhood of resi-
dence was described as “suburban” by 42.7%, “urban” by
40% and “rural” by 15.3% of respondents. Overall, 88% of
IDUs indicated they had ever received a HCV test, and
73.8% had done so in the past year. Respondents who had
reported HCV testing in the past year were asked to spe-
cify the location where they received a HCV test most re-
cently. Of 329 PWID tested in the past year, 64 (19.5%)
received their test at the SEP. Nearly one third (32.5%)received testing at a primary care medical clinic, and 34
(10.3%) received testing in a correctional facility. The
remaining respondents reported they received testing at
other health care and public health venues.
Table 2 shows the results of univariate and multivariate lo-
gistic regression models measuring the association of past-
year HCV testing and selected participant characteristics.
Those who reported recent testing were more likely to live
in urban or suburban areas, to have health insurance, and to
have received some education beyond high school. There
were no differences in past-year testing according to age,
gender, or race. In the final, adjusted model, having a pri-
mary care provider (PCP) was independently associated with
past-year HCV testing (adjusted OR 2.0, 95% C.I. 1.3 – 3.0),
as was higher educational attainment (adjusted OR 1.9, 95%
C.I. 1.4 – 2.5), residence in Milwaukee (adjusted OR 2.3,
95% C.I. 1.5 – 3.5), and lifetime occurrence of opioid over-
dose (adjusted OR 1.8, 95% C.I. 1.1 – 2.8). Moreover, among
those who had a PCP, those attending a medical appoint-
ment with a PCP during the six months before the study
had nearly three times greater odds of having been tested
for HCV (univariate OR 2.9, 95% C.I. 1.3 – 6.4).
Qualitative results
Of the 553 individuals who agreed to complete the survey,
362 (65% of survey respondents) also responded to the
brief interview questions. Of 31 respondents that com-
pleted the brief interview who reported having a previous
positive test for HCV, 13 had been aware of their positive
antibody status for more than 1 year, and were excluded
from past-year testing analysis. Barriers and facilitators to
past-year testing derived from thematic analysis of these
responses are shown in Table 3 and Table 4, respectively.
There were few differences in the type and frequency
of barriers reported by PWID who were tested in the
past year compared to those who were not. The fre-
quency of codes representing facilitators of HCV testing
was also similar among respondents in the two groups.
Commonly-reported barriers and facilitators, emphasized
with illustrative quotations, are described below.
Based on responses to the interview questions, we ob-
served that many PWID described an internal motivation
regarding their own and/or another person’s health that
influenced their decision to get tested for HCV. One per-
son who had been tested in the past year stated:
Knowing [my HCV status] is something that I need to do
to stay healthy. Knowing that I’ll feel better about myself
if the results are good makes it easier to get tested.
Similarly, lack of awareness of one’s HCV status was de-
scribed as a source of anxiety for some respondents. One
who had not been tested in the past year bluntly stated,
“Not knowing sucks. It doesn’t feel good when you don’t
Table 1 Characteristics of sample, by receipt of HCV test
in the past year (N = 520)





Overall number of subjects 136 (26.2) 384 (73.8)
Age
<30 years 62 (28.2) 158 (71.8)
0.37
≥30 years 74 (24.7) 226 (75.3)
Gender
Male 98 (27.5) 259 (72.5)
0.32
Female 38 (23.3) 125 (76.7)
Race
White 108 (26.4) 301 (73.6)
0.80
Non-white 28 (25.2) 83 (74.8)
Employment status
Unemployed 90 (28.3) 228 (71.7)
0.27Employed – part time 23 (25.6) 67 (74.4)
Employed – full time 23 (20.5) 89 (79.5)
Has health insurance
No 84 (30.4) 192 (69.6)
0.02
Yes 52 (21.3) 192 (78.7)
Has a primary
care provider
No 88 (31.7) 190 (68.3)
<0.01
Yes 48 (19.8) 194 (76.7)
Area of residence
Rural 27 (33.8) 53 (66.2)
0.05Suburban 64 (28.8) 158 (71.2)
Urban 44 (21.2) 164 (78.8)
Milwaukee zip code
No 80 (33.2) 161 (66.8)
<0.01
Yes 56 (20.1) 223 (79.9)
Education
Did not finish HS 31 (40.3) 46 (59.7)
<0.01
GED or high school
diploma
67 (31.9) 143 (68.1)
Some college/technical
school
29 (17.2) 140 (82.4)
Graduated college/
technical school
9 (14.1) 55 (85.9)
Years since initiation
of injection drug use
Less than 2 years 40 (32.5) 83 (67.5)
0.192-5 years 50 (23.7) 161 (76.2
More than 5 years 46 (24.7) 140 (75.3)
Frequency of injection drug
use within the past 6 months
Once per week or less 17 (34.0) 33 (66.0)
0.24
2-6 times/week 33 (29.5) 79 (70.5)
Table 1 Characteristics of sample, by receipt of HCV test
in the past year (N = 520) (Continued)
Once daily or more 86 (24.3) 268 (75.7)
Shared works in past
6 months**
No 59 (26.8) 161 (73.2)
0.77
Yes 77 (25.7) 223 (74.3)
History of opioid overdose
No 105 (28.9) 259 (71.2)
0.05
Yes 31 (20.4) 121 (79.6)




All values are n (%) unless otherwise noted.
*P value from chi-squared of independence between selected covariate and
receipt of HCV test in the preceding 12 months.
**Sharing works was defined as any report of using a syringe, cooker/container,
or cotton filter after another person had already used it.
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sense of altruism regarding potential health consequences
their drug use may have for significant others and
community-at-large, and cited this as motivation to seek
HCV testing. One participant who had not recently been
tested stated, “Knowing that there’s an epidemic and that
it can be passed on [makes it easier to get tested].” An-
other participant who had been tested said, “if I knew I
was positive, then I would take caution to not infect my
family.” While such comments may not reflect accurate
knowledge of how HCV is transmitted, they demonstrate
a role that concern for others may play in the decision to
be tested for HCV.
Respondents commonly reported that fear was an im-
portant psychological barrier to HCV testing. Simply being
“not ready” was a common response and numerous PWID
indicated they were “scared of the result.” One recently
tested participant remarked, “I worry about Hep C more
than HIV. I’m afraid of what the result might be.” One in-
dividual not tested in the past year admitted, “I’m in denial.
I don’t want to hear that I have it”.
While some were fearful of their result, others per-
ceived their risk of contracting HCV as low despite
injecting drugs and, therefore, considered HCV testing
unnecessary. Low risk assessments were based on 1)
never sharing needles, 2) lack of symptoms, and 3) prior
negative test result.
Health care factors played an important role in the deci-
sion of many PWID to undergo HCV testing. Several re-
spondents pointed to the accessibility of nonjudgmental
care providers (i.e., mobile testing, SEPs, and PCPs) as an
important facilitator of HCV screening. Those who found
HCV testing “easy” described having regular contact and a
positive rapport with their primary care provider. One tested
individual explicitly stated this as a facilitator to testing: “I’m
Table 2 Factors associated with receiving an HCV test





Age <30 years 1.2 (0.8 – 1.8)
Female gender 1.2 (0.8 – 1.9)
Completed college or
technical school
1.9 (1.5 – 2.5) 1.9 (1.4 – 2.5)
Currently employed* 1.3 (0.9 – 2.0)
Has health insurance 1.6 (1.1 – 2.4)
Has a primary care provider 1.9 (1.2 – 2.8) 2.0 (1.3 – 3.0)
Urban residence** 1.6 (1.1 – 2.4)
Milwaukee zip code 2.0 (1.3 – 2.9) 2.3 (1.5 – 3.5)
History of opioid overdose 1.6 (1.0 – 2.5) 1.8 (1.1 – 2.8)
Injecting for 2 or more years 1.5 (1.0 – 2.4)
Injecting daily during
past 6 months***
1.4 (0.9 – 2.1)
Sharing works in
past 6 months±
1.1 (0.7 – 1.6)
*Employed full- or part-time as compared with unemployed.
**Compared to a collapsed single group of rural and suburban.
***Compared to a collapsed single group of people who injected less than
daily (i.e. combined once a week and 2–6 times a week.
±Sharing works was defined as any report of using a syringe, cooker/container, or
cotton filter after another person had already used it.






Overall number of subjects
(N = 349)
260 (74.5) 89 (25.5)
Barriers by code**
Fear of positive test 27 (9.2) 8 (7.5) 0.58
Perceived risk 3 (1.0) 4 (3.7) 0.07
Stigma associated with
HCV and/or IVDU
4 (1.4) 3 (2.8) 0.33
Lab characteristic 13 (4.5) 3 (2.8) 0.46
Lack of access to
transportation
48 (16.4) 15 (14) 0.56
Time constraints 31 (10.6) 14 (13.1) 0.49
Lack of knowledge
of testing
27 (9.2) 11 (10.3) 0.76
Cost 30 (10.3) 11 (10.3) 1.00
Lack of access to MD/PCP 3 (1.0) 0 (0) 0.30
Not having to
take initiative
1 (0.3) 1 (0.9) 0.46
Lack of rapport
with provider
0 (0) 2 (1.9) 0.02
Confidentiality 2 (0.7) 1 (0.9) 0.80
Lack of motivation 5 (1.7) 5 (4.7) 0.09
Other 2 (0.7) 1 (0.9) 0.80
No barriers identified 96 (33) 28 (26.2) 0.20
All values are n (%) unless otherwise noted.
*P value from chi-squared of independence between selected barrier and
receipt of HCV test in the preceding 12 months.
**Some respondents reported more than one barrier.
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with my doctor.” Some appreciated having screening offered
to them as part of routine health maintenance rather than
having to take the initiative to ask for testing. One tested in-
dividual answered that “when it’s [HCV testing] offered to
me on a regular basis [it makes it easier to get tested].” A
nonjudgmental and confidential atmosphere was reported
to be a facilitator of HCV testing in both traditional medical
clinics and community-based settings. Participants identified
community-based organizations such as the SEP, mobile
testing, and public health departments as organizations that
facilitated HCV screening. One individual tested in the last
3 months stated, “I can come here [SEP] and the staff does
it for free and it’s confidential.” Similarly, “having a safe en-
vironment where people aren’t going to ‘notice you’, such as
here [SEP], where you know that other people are here for
the same reason” provided participants with comfort and
eased their concerns about testing.
Most participants who discussed their experience at a
SEP felt that the program provided a safe environment,
which fostered communication and improved feasibility of
testing. Few participants reported negative experiences in
health care settings as barriers to receiving HCV testing.
Stigma associated with both injection drug use as well as
HCV infection was a barrier among these participants.
Those who identified stigma as a barrier used words such
as “shame,” “embarrassment,” and “taboo” to describe their
experiences. Negative feelings such as embarrassment or afeeling that one is being judged were perceived obstacles to
seeking HCV testing. One participant who had never been
tested stated:
People know that most of the time you get tested for Hep
C because you’re an IV user. People judge you no matter
what your results are. That’s the worst feeling ever.
Participants identified other tangible perceived barriers
and facilitators to testing. Independent of past-year test-
ing, lack of transportation, time constraints, lack of
knowledge surrounding testing, and cost of the test were
identified barriers. Conversely, access to transportation,
awareness of testing locations, and availability of free
testing were facilitating factors for both groups.
Discussion
In this cross-sectional survey of PWID in Wisconsin, we
found that most respondents had been previously tested
for HCV. Those who were tested for HCV in the past year
were more likely to have a PCP, to have completed some
education beyond high school, and to reside in the city of
Milwaukee. Qualitative analysis of interview responses
Table 4 Facilitators to past year HCV testing (N = 349)
Tested in past
12 m









65 (15.4) 12 (12.5) 0.47
Perceived risk 15 (3.6) 3 (3.1) 0.83
Lab characteristic 15 (3.6) 3 (3.1) 0.83
Access to
transportation
36 (8.6) 11 (11.5) 0.37
Mobile testing
center/SEP
75 (17.8) 13 (13.5) 0.31
Adequate time 9 (2.1) 4 (4.2) 0.25
Knowledge of testing 25 (6.7) 9 (9.4) 0.22
Free testing 85 (20.2) 13 (13.5) 0.13
Access to MD/PCP 28 (6.7) 5 (5.2) 0.60
Not having to take
initiative
5 (1.2) 0 (0) 0.28
Rapport with provider 10 (2.4) 2 (2.1) 0.86
Confidentiality 8 (1.9) 1 (1.0) 0.56
Motivation 5 (1.2) 1 (1.0) 0.90
Other 16 (3.8) 8 (8.3) 0.06
Nothing 24 (5.7) 11 (11.5) 0.04
All values are n (%) unless otherwise noted.
*P value from chi-squared of independence between selected facilitator and
receipt of HCV test in the preceding 12 months.
**Some respondents reported more than one facilitator.
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health care access in general to facilitate regular screening
for PWID. The findings from our study may provide
insight into individual- and structural-level barriers and
facilitators to routine testing for high-risk individuals, and
inform future efforts to promote HCV testing among
PWID.
Compared with respondents from other Wisconsin
cities, residents of Milwaukee had more than twice the
odds of receiving HCV testing in the year prior to the
study. Numerous factors may account for this disparity:
Milwaukee is the largest and most densely populated city
in Wisconsin and has a higher burden of communicable
diseases such as HIV and sexually transmitted infections
than most other areas of the state. Appropriately, pre-
vention services such as the Lifepoint Needle Exchange
are more numerous and accessible to Milwaukee resi-
dents, and PWID in this area may therefore have greater
knowledge of available resources. Additionally, individ-
uals living in cities with a higher burden of drug use and
HCV may be more likely to encounter peers who have
utilized prevention services in the past, to have medical
providers who have greater familiarity with the needs ofdrug-using patients, and to have easier access to pri-
mary care or urgent care centers where testing can be
performed. There may be unmet needs for community-
based services and a paucity of health care providers
with experience caring for PWID in less densely popu-
lated areas.
We found quantitative evidence that access to health
care is an important determinant of regular HCV screen-
ing for PWID. Respondents who reported that they have a
primary care provider had twice the odds of receiving a
test for HCV in the past year as those without at PCP.
Though there was no difference in past-year testing, both
groups commonly identified access to healthcare profes-
sionals as a facilitator to testing. Previous research has
noted that continuity of care with a provider has fostered
regular screening and, in some cases, adherence to treat-
ment [18]. Our results suggest that PWID are more apt to
receive HCV screening when it is offered as a part of rou-
tine care, rather than when it is only available “on-de-
mand,” thereby requiring individuals to take initiative for
screening themselves. This is consistent with a recent
qualitative study indicating that provider-initiated HCV
screening is substantially more successful than self-
initiated screening among drug users in New York and
San Francisco [19]. The previous study, involving focus
groups of drug users recruited in both clinical and non-
clinical settings, found that while provider-initiated HCV
screening was more successful, there was a perceived lack
of settings for self-initiated HCV testing yet an eagerness
to have access to voluntary testing. This differed from test-
ing for HIV, which individuals perceived as much more
easily accessible and were more likely to seek based on
their own initiative. While we cannot determine from our
data whether HCV testing in Wisconsin is more commonly
provider-initiated or patient-initiated, our findings highlight
a potentially important role that PCPs have in screening for
HCV. Particularly, PCPs could initiate the discussion by
talking about the benefits of testing, providing information
regarding voluntary testing locations, and being explicit
about the lack of judgment on the part of the practitioner.
Study participants reported a range of beliefs related to
HCV testing, many of which are consistent with previous
work on HIV and HCV testing [20-23]. Fear of a positive
test result played a role in the decision of many respondents
who were resistant to testing. Low perceived risk also
contributed to past-year testing in some cases. Medical
providers and SEP staff can be instrumental in support-
ing participants’ testing in both of these groups. Staff
can allay fears about a positive result by citing new
HCV treatments as well as support group if found to
be HCV positive. Motivational interviewing techniques
providing feedback regarding drug-injecting behaviors
and actual HCV risk may be useful to help those with
perceived low risk get tested [24].
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to HCV testing, which is consistent with previous research
[23]. Participants in our study did not frequently express
concerns about stigma from medical professionals or
needle-exchange staff, as has been reported previously
[25-27]. In fact, nearly one-third of those tested in the past
year in our study had been tested in primary care clinics.
Based on our data, it does not appear that healthcare set-
tings are a major impediment to testing. Rather, in depth
analysis of “stigma” statements revealed that those respon-
dents described perceiving a more generalized, societal
stigma of HCV as a “junkie disease” [25]. This perception
highlights an opportunity for health care providers and
community-based organizations to help foster safe and
accepting environments for testing. This may include assur-
ances of confidentiality, education campaigns regarding
other risk factors for HCV, and improved provider-patient
communication.
There are several limitations to our study. Despite having
a large sample size and a reasonably high response rate of
64%, the respondents to our survey were a convenience
sample, which may not be fully representative of PWID in
the communities we targeted. Our study was performed in
a single Midwestern state with a mix of rural, suburban,
and urban participants. The findings, therefore, may
not be generalizable to drug-using communities in
other regions. As all participants were clients at a SEP,
our study sample may exclude a subset of PWID who
do not use prevention services and may have a higher
risk of HCV. While we attempted to minimize bias due
to socially-desirable responding by having participants
privately self-administer most sections of the survey,
the responses to the in-person interview questions may
have been influenced by participants’ knowledge of the
study’s main goal, which was to collect information useful
for promoting HCV testing among PWID who have not
been tested previously.
In theory, early detection of HCV can facilitate referrals
to treatment and may reduce the future burden of mor-
bidity from liver disease and even decrease HCV transmis-
sion [28]. In the past, treatment for HCV has not been
widely available or affordable to PWID, many of whom
lack health insurance and generally have poor access to
health services. Linking PWID who test positive for HCV
to care and evaluating for treatment may, therefore, be dif-
ficult. However, currently evolving health insurance re-
forms could eventually make HCV treatment available to
a growing number of patients. In this setting, strategies to
improve detection of asymptomatic HCV infection as part
of routine primary care could yield substantial public
health benefit. Moreover, some evidence suggests that de-
tection of asymptomatic infection and subsequent educa-
tion may lead to safer injection practices and reduce
frequency of injecting among high-risk PWID, therebypromoting HCV prevention even among those who do
not access treatment [29,30].
Conclusions
Our study suggests that access to medical and preventive
health services that are responsive to the needs and vul-
nerabilities of people who inject drugs are important de-
terminants of HCV testing among PWID. Increasing the
proportion of PWID who receive screening for HCV in
the future will require expanding access to programs that
provide voluntary counseling and testing, and promoting
recognition among medical providers that HCV screening
is an important part of routine preventive care. Given that
a plurality of PWID previously tested for HCV in our
study had been tested in clinical settings, increasing access
to primary care is an important strategy for detecting pre-
viously undiagnosed cases of HCV. For PWID who are
not routinely engaged in medical care, SEPs may also be
an underutilized resource for HCV screening.
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